1. Home
  2. SUIG vs IBIO Comparison

SUIG vs IBIO Comparison

Compare SUIG & IBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Sui Group Holdings Limited

SUIG

Sui Group Holdings Limited

N/A

Current Price

$0.85

Market Cap

91.4M

Sector

Finance

ML Signal

N/A

Logo iBio Inc.

IBIO

iBio Inc.

HOLD

Current Price

$1.39

Market Cap

83.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SUIG
IBIO
Founded
2006
2008
Country
United States
United States
Employees
N/A
N/A
Industry
Finance Companies
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
91.4M
83.5M
IPO Year
2022
2009

Fundamental Metrics

Financial Performance
Metric
SUIG
IBIO
Price
$0.85
$1.39
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
4
Target Price
$5.75
$4.75
AVG Volume (30 Days)
272.9K
608.3K
Earning Date
05-07-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
73.08
EPS
N/A
N/A
Revenue
$3,898,631.00
N/A
Revenue This Year
$49.95
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
18.10
N/A
52 Week Low
$0.80
$0.67
52 Week High
$7.25
$3.82

Technical Indicators

Market Signals
Indicator
SUIG
IBIO
Relative Strength Index (RSI) 34.65 43.98
Support Level $0.83 $1.29
Resistance Level $1.54 $1.80
Average True Range (ATR) 0.07 0.09
MACD 0.01 0.01
Stochastic Oscillator 34.37 44.00

Price Performance

Historical Comparison
SUIG
IBIO

About SUIG Sui Group Holdings Limited

Sui Group Holdings Ltd operates a treasury management business. It has established a publicly traded SUI treasury, backed by an exclusive relationship with the Sui Foundation, an independent organization dedicated to the advancement and adoption of the Sui network. The company executes its business by acquiring SUI tokens through open-market purchases, institutional-grade deal flow typically reserved for cryptocurrency funds, and a negotiated purchase agreement with the Sui Foundation. It is focused on capitalizing on technology trends and ecosystem growth relating to SUI, while providing liquid and institutional-grade access to blockchains. The company has one reportable segment, which is a digital asset platform focused on maximizing SUI per share value and advancing the Sui ecosystem.

About IBIO iBio Inc.

iBio Inc is a preclinical stage biotechnology company that leverages the power of Artificial Intelligence (AI) for the development of precision antibodies. CDMO. Its technology stack is designed to minimize downstream development risks by employing AI-guided epitope-steering and monoclonal antibody (mAb) optimization.

Share on Social Networks: